KYLIE PARSHALL: Open Payments
NPI 1023407350 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,439 in 145 payments from 26 companies in 2025. Trend: 2023 $2,456 · 2024 $2,107 · 2025 $2,439
Food & beverage: $2,264Consulting: $175
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $364 |
| Amgen Inc. | 17 | $332 |
| Novo Nordisk Inc | 16 | $273 |
| PFIZER INC. | 16 | $257 |
| AstraZeneca Pharmaceuticals LP | 6 | $223 |
| Otsuka America Pharmaceutical, Inc. | 16 | $184 |
| Axsome Therapeutics, Inc. | 10 | $151 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $136 |
| Seqirus USA Inc | 2 | $61 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $55 |
Products named: VRAYLAR, REXULTI, Wegovy, PROLIA, XIFAXAN, BREZTRI, NURTEC ODT, OTEZLA.
Industry payments across NE — which companies pay providers there.
